Results 231 to 240 of about 1,566,402 (309)
ABSTRACT Some autistic individuals camouflage their behavioral differences, a phenomenon that overlaps with general impression management (IM). Few studies have examined IM in autistic people, particularly outside English‐speaking countries. This study delineated the shared facets of camouflaging and IM, and used this conceptual clarification to ...
Wei Ai +8 more
wiley +1 more source
ABSTRACT Physical activity is critical for health, yet many adolescents do not engage in regular activity. Youth with autism spectrum disorder (ASD) and intellectual disability (ID) may be at heightened risk due to motor, sensory, and social barriers, but less is known about complete disengagement.
Daniel E. Lidstone
wiley +1 more source
Aims Graduating medical students consistently report being unprepared for the complexity of prescribing in clinical practice. Current clinical prescribing teaching and authentic assessment are limited due to patient safety concerns. We aimed to examine the educational utility of supervised preprescribing as a learning process and potential authentic ...
Kellie A. Charles +7 more
wiley +1 more source
Abstract Aims Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life‐threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK‐wide survey of local hospital protocols for the use of andexanet alfa suggested that practice ...
Louis Fisher +11 more
wiley +1 more source
Aim To explore the practices, confidence and perspectives of community pharmacists in deprescribing high‐risk psychotropic medicines, including opioid analgesics, benzodiazepine, gabapentinoids and medicinal cannabis. Methods An anonymous, cross‐sectional national online survey was conducted between January and April 2025 among Australian community ...
Monica Jung +5 more
wiley +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Abstract Health care is shifting towards a digital‐guided system, integrating digital diagnostics, biomarkers and therapeutics in many care pathways. However, despite rapid technological advancement and preliminary adoption accelerated by the COVID‐19 pandemic, a significant implementation gap persists. This narrative review explores the causes of this
Mees H. P. Stoop +3 more
wiley +1 more source
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway +24 more
wiley +1 more source
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough +29 more
wiley +1 more source

